See more : Energy Transfer LP (ET-PC) Income Statement Analysis – Financial Results
Complete financial analysis of NGM Biopharmaceuticals, Inc. (NGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NGM Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Medios AG (MEDOF) Income Statement Analysis – Financial Results
- Fitvia Corp. (BRZV) Income Statement Analysis – Financial Results
- Garanti Faktoring A.S. (GARFA.IS) Income Statement Analysis – Financial Results
- World Wireless Communications, Inc. (WWRL) Income Statement Analysis – Financial Results
- Next.e.GO N.V. Ordinary Shares (EGOXF) Income Statement Analysis – Financial Results
NGM Biopharmaceuticals, Inc. (NGM)
About NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.42M | 55.33M | 77.88M | 87.37M | 103.54M | 108.67M | 77.14M | 85.59M |
| Cost of Revenue | 2.22M | 5.98M | 7.90M | 163.97M | 129.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.20M | 49.35M | 69.98M | -76.60M | -25.71M | 108.67M | 77.14M | 85.59M |
| Gross Profit Ratio | 49.72% | 89.19% | 89.86% | -87.68% | -24.83% | 100.00% | 100.00% | 100.00% |
| Research & Development | 112.01M | 181.07M | 161.71M | 163.97M | 129.25M | 95.71M | 79.74M | 82.11M |
| General & Administrative | 37.84M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Selling & Marketing | -1.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.74M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Other Expenses | -234.00K | -132.00K | -60.00K | -593.00K | -147.00K | 199.00K | -152.00K | 133.00K |
| Operating Expenses | 148.74M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Cost & Expenses | 150.96M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Interest Income | 9.32M | 3.71M | 420.00K | 1.94M | 6.69M | 3.62M | 2.36M | 1.81M |
| Interest Expense | 0.00 | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.22M | 4.04M | 6.09M | 6.56M | 7.61M | 7.22M | 6.44M | 3.53M |
| EBITDA | -144.33M | -166.25M | -120.70M | -103.83M | -49.34M | 2.91M | -10.98M | -4.83M |
| EBITDA Ratio | -3,267.51% | -300.45% | -154.97% | -118.85% | -47.65% | 2.68% | -14.24% | -5.64% |
| Operating Income | -146.55M | -166.25M | -120.70M | -103.83M | -49.34M | -4.31M | -17.43M | -8.36M |
| Operating Income Ratio | -3,317.79% | -300.45% | -154.97% | -118.85% | -47.65% | -3.97% | -22.59% | -9.77% |
| Total Other Income/Expenses | 4.17M | 3.58M | 360.00K | 1.35M | 6.55M | 3.82M | 2.21M | 1.94M |
| Income Before Tax | -142.38M | -162.67M | -120.34M | -102.49M | -42.80M | -493.00K | -15.22M | -6.42M |
| Income Before Tax Ratio | -3,223.34% | -293.98% | -154.51% | -117.30% | -41.33% | -0.45% | -19.73% | -7.50% |
| Income Tax Expense | 0.00 | -3.58M | -6.51M | -8.49M | -14.30M | 3.82M | -1.06M | 500.00K |
| Net Income | -142.38M | -159.09M | -113.83M | -93.99M | -28.50M | -493.00K | -14.16M | -6.92M |
| Net Income Ratio | -3,223.34% | -287.50% | -146.15% | -107.58% | -27.52% | -0.45% | -18.35% | -8.09% |
| EPS | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| Weighted Avg Shares Out | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
| Weighted Avg Shares Out (Dil) | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
NGM Biopharmaceuticals (NYSE:NGM) Shares Sold by UBS Group AG
JPMorgan Chase & Co. Sells 41,823 Shares of NGM Biopharmaceuticals (NYSE:NGM)
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Greek Ship Managers Shun Venezuela Trade as U.S. Sanctions Bite
Russell Investments Group Ltd. Makes New $396,000 Investment in NGM Biopharmaceuticals (NYSE:NGM)
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
Intercept Pharmaceuticals: Undervalued Ahead Of An Eventful Period (NASDAQ:ICPT)
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
NGM Biopharmaceuticals: A Unique NASH Business Model To Watch
Viking Therapeutics Inc (NASDAQ: VKTX) Q1 2020 Earnings Call Transcript | AlphaStreet
Source: https://incomestatements.info
Category: Stock Reports